Attention deficit hyperactivity disorder

Update information

March 2018: Changes have been made to align this quality standard with the updated NICE guideline on attention deficit hyperactivity disorder. Statement 5 on psychological treatments for children and young people was removed and changes have been made to the data sources, definitions and source guidance sections throughout.

Minor changes since publication

October 2021: Source guidance for statements 6 and 7 have been updated because the technology appraisal guidance on methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98) has been updated and replaced by recommendations 1.7.7 to 1.7.10 in the NICE guideline on attention deficit hyperactivity disorder.